IL36239A - 4-hydroxy-4-(2-oxo-3-tetrahydrofuryl)piperidine and its preparation - Google Patents
4-hydroxy-4-(2-oxo-3-tetrahydrofuryl)piperidine and its preparationInfo
- Publication number
- IL36239A IL36239A IL6836239A IL3623968A IL36239A IL 36239 A IL36239 A IL 36239A IL 6836239 A IL6836239 A IL 6836239A IL 3623968 A IL3623968 A IL 3623968A IL 36239 A IL36239 A IL 36239A
- Authority
- IL
- Israel
- Prior art keywords
- formula
- hydroxy
- tetrahydrofuryl
- oxo
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Description
4-Hydroxy-4-(2-oxo-3-tetrahydrofuryl) piperidin© and its preparation SANDOZ A.G.
The present invention relates- to a new piperidine derivative and a process for the production thereof.
The present invention provides ^-hydroxy-2!- (2-oxo-3_tetra-h drofuryl) iperidine of the formula I, . The present invention further provides the following process for the production of -hydroxy- - (2-0x0-3-tetrahydrofuryl)-piperidine of formula 1 comprising reacting l-benzyl- -piperidone of formula II, with γ-butyrolactone of formula III in the presence of an alkali metal amide and debenzylating the resulting l~benzyl- -hydroxy- - (2-oxc>-3-tetrahydrofuryl)piperidiiae.
The alkali metal amide is preferablv lithium amide, the reaction being effected in liquid ammonia and/or absolute ether or absolute dioxane.
The debenzylation may be effected by catalytic hydrogena-tion e.g. in glacial acetic acid in the presence of a palladium catalyst preferably at a slightly elevated pressure and at an elevated temperature, for example, 6 atmospheres and 60°C.
The compounds of formulae II and III are described in the literature.
The compound of formula I is useful as an intermediate in the production of pharmaceutically active compounds of general formula ivy the trifluoromethyl, cyano or a lower alkanoyl radical of 1 to h carbon atoms, and signifies a hydrogen atom or a methyl radical. and pharmaceutically acceptable acid addition salts thereof with inorganic or organic acids.
The compounds of formula IV and their pharmaceutically acceptable acid addition salts may be produced by heating a compound of formula V, V in which and Rg have the above significance, and X signifies chlorine, bromine^ iodine or a radical of an organic sulphonie acid, e.g. £-toluenesul- phonic acid, with the compound of formula I in the presence of an acid binding agent.
Heating is effected for between 10 and 50 hours in absolute toluene, absolute xylene or in another anhydrous organic solvent, e.g. to the boil at reflux while stirring at normal pres-sure, or in a bomb tube to temperatures of 130-180°C. An inorganic base, e.g. potassium carbonate, a tertiary organic base or a second ol of compound I may be used as acid binding agent.
In the following non-limitative Example all temperatures are indicated in degrees Centigrade and are uncorrected.
EXAMPLE . -Hydroxy- - (2-oxo- -tetrahydrofuryl)plperldine a) l-benzyl- 4-hydroxy~ ¾~ (2-oxo-3-tetrahydrofuryl)piperidine. r A mixture of 57.8 g of l-benzyl-4-piperidone and 68.8 g of y -butyrolactone is added drop ise to a" suspension of lithium amide (produced from 2.8 g of lithium) in 700 cc of liquid ammonia. The mixture is stirred for 1 hour at the temperature of the liquid ammonia and the ammonia is then allowed to evaporate with the simultaneous dropwise addition of 500 cc of toluene. 200 cc of a 20 # aqueous ammonium chloride solution are subsequently added dropwise to the reaction mixture and the organic layer is separated. The aqueous phase is filtered through diatomaceous earth and extracted once with toluene ; the combined organic phases are dried over sodium sulphate and concentrated by evaporation. The crude l-benzyl-¼-hydroxy-H- (2-oxo-3-tetrahydrofuryl)piperidine obtained as residue is recrystal- lized from benzene/petroleum ether and has a M.P. of 108-109* . b) 4-hydroxy- ¾- (2-oxo-3-tetrahydrofuryl)piperidine. 9· 7 g of l-benzyl-4-hydroxy- ¾-(2-cxo-3~tetrahydrofuryl)- piperidine are dissolved in 100 cc of glacial acetic acid and hydro- genated in the presence of 1.0 g of a palladium catalyst (10 on charcoal) at an initial pressure of 6 atm. and a temperature of 60* . The taking up of hydrogen is completed after 5 hours. The catalyst is filtered off, the filtrate is concentrated by evaporation at reduced pressure, the viscous residue is taken up in 200 cc of chloroform and a solution of 70 g of potassium carbonate in 70 cc of water is a'dded to the resulting solution while stirring vigorously. The mixture is stirred for 15 minutes, is subsequently filtered through diatomaceous earth, the organic phase of the filtrate is The combined chloroform extracts are dried over sodium sulphate and concentrated by evaporation; the crystalline residue is dried in a high vacuum at JO*. Crude 4-hydroxy-A-(2-oxo-3-'tetrahydrofuryl)-piperidine, having a M.P. of 158-l½Oe, is obtained and is further worked up without purification.
Claims (5)
1. A process for the production of a compound of formula comprising reacting l-benzyl-4-piperidone of formula II, with r-butyrolactone of formula III, in the presence of an alkali metal amide and debenzylating the resulting l-benzyl- -hydroxy- - (2-oxo-5-tetrahydrofuryl)piperidine.
2. A process according to Claim 1, wherein the alkali metal amide is lithium amide, the reaction being effected in liquid ammonia and/or absolute ether or absolute dioxane.
3. · A process for the production of the compound of formula I, stated in Claim 1, substantially as herein described with reference to the Example.
4. The compound of formula I, stated in Claim 1, whenever produced by a process according to any of the preceding Claims.
5. The compound of formula I, stated in Claim 1. For the Applicants REiNHOiD COfQ HD PAblNlfc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH558967A CH497458A (en) | 1967-04-19 | 1967-04-19 | Process for the preparation of new phenothiazine derivatives |
| CH1705667 | 1967-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL36239A true IL36239A (en) | 1971-06-23 |
Family
ID=25698043
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL6836239A IL36239A (en) | 1967-04-19 | 1968-04-17 | 4-hydroxy-4-(2-oxo-3-tetrahydrofuryl)piperidine and its preparation |
| IL6829842A IL29842A (en) | 1967-04-19 | 1968-04-17 | Phenothiazine derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL6829842A IL29842A (en) | 1967-04-19 | 1968-04-17 | Phenothiazine derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US3531480A (en) |
| AT (2) | AT292726B (en) |
| AU (2) | AU5480273A (en) |
| BE (1) | BE713802A (en) |
| BG (1) | BG17326A3 (en) |
| CH (1) | CH497458A (en) |
| DE (1) | DE1770218A1 (en) |
| ES (1) | ES352822A1 (en) |
| FR (1) | FR1583822A (en) |
| GB (2) | GB1223315A (en) |
| IE (2) | IE32169B1 (en) |
| IL (2) | IL36239A (en) |
| NL (1) | NL6804983A (en) |
| NO (1) | NO124997B (en) |
| OA (1) | OA03386A (en) |
| RO (1) | RO54395A (en) |
| SE (2) | SE356520B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3857943A (en) * | 1969-03-27 | 1974-12-31 | May & Baker Ltd | New phenothiazine derivatives in the treatment of spasticity of muscles |
| CH511886A (en) * | 1969-07-08 | 1971-08-31 | Sandoz Ag | Process for the production of new furanone derivatives |
| US20040259866A1 (en) * | 1998-06-30 | 2004-12-23 | Snutch Terrance P. | Calcium channel blockers comprising two benzhydril moieties |
| US6310059B1 (en) | 1998-06-30 | 2001-10-30 | Neuromed Technologies, Inc. | Fused ring calcium channel blockers |
| WO2007133481A2 (en) * | 2006-05-11 | 2007-11-22 | Neuromed Pharmaceuticals Ltd. | Method for increasing the bioavailability of benzhydryl piperazine containing compounds |
| US8409560B2 (en) | 2011-03-08 | 2013-04-02 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| JP2014507424A (en) | 2011-03-08 | 2014-03-27 | ザリカス ファーマスーティカルズ リミテッド | Solid dispersion formulation and method of use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1212031A (en) * | 1957-10-21 | 1960-03-21 | Rhone Poulenc Sa | Phenothiazine derivatives substituted on nitrogen with a basic chain comprising a heterocycle and their preparation |
-
1967
- 1967-04-19 CH CH558967A patent/CH497458A/en not_active IP Right Cessation
-
1968
- 1968-03-11 GB GB40359/70A patent/GB1223315A/en not_active Expired
- 1968-03-11 GB GB01783/68A patent/GB1223314A/en not_active Expired
- 1968-04-09 NL NL6804983A patent/NL6804983A/xx unknown
- 1968-04-10 SE SE04843/68A patent/SE356520B/xx unknown
- 1968-04-10 SE SE05102/71A patent/SE361884B/xx unknown
- 1968-04-16 NO NO681425A patent/NO124997B/no unknown
- 1968-04-17 US US721949A patent/US3531480A/en not_active Expired - Lifetime
- 1968-04-17 DE DE19681770218 patent/DE1770218A1/en active Pending
- 1968-04-17 AT AT374668A patent/AT292726B/en not_active IP Right Cessation
- 1968-04-17 IL IL6836239A patent/IL36239A/en unknown
- 1968-04-17 AT AT1201369A patent/AT293372B/en not_active IP Right Cessation
- 1968-04-17 BE BE713802D patent/BE713802A/xx unknown
- 1968-04-17 IL IL6829842A patent/IL29842A/en unknown
- 1968-04-17 IE IE444/68A patent/IE32169B1/en unknown
- 1968-04-17 ES ES352822A patent/ES352822A1/en not_active Expired
- 1968-04-17 IE IE637/71A patent/IE32170B1/en unknown
- 1968-04-17 BG BG9805A patent/BG17326A3/xx unknown
- 1968-04-18 FR FR148511A patent/FR1583822A/fr not_active Expired
- 1968-04-18 RO RO196856492A patent/RO54395A/ro unknown
- 1968-04-19 OA OA53262A patent/OA03386A/en unknown
-
1973
- 1973-04-19 AU AU54802/73A patent/AU5480273A/en not_active Expired
- 1973-04-19 AU AU54801/73A patent/AU5480173A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| SE356520B (en) | 1973-05-28 |
| US3531480A (en) | 1970-09-29 |
| FR1583822A (en) | 1969-12-05 |
| GB1223314A (en) | 1971-02-24 |
| IE32170L (en) | 1968-10-19 |
| IE32169B1 (en) | 1973-05-02 |
| GB1223315A (en) | 1971-02-24 |
| DE1770218A1 (en) | 1971-10-14 |
| RO54395A (en) | 1973-02-17 |
| AU5480173A (en) | 1973-07-12 |
| IL29842A0 (en) | 1968-06-20 |
| BG17326A3 (en) | 1973-07-25 |
| IE32170B1 (en) | 1973-05-02 |
| AU5480273A (en) | 1973-07-12 |
| AT292726B (en) | 1971-09-10 |
| IE32169L (en) | 1968-10-19 |
| IL29842A (en) | 1971-05-26 |
| AT293372B (en) | 1971-10-11 |
| CH497458A (en) | 1970-10-15 |
| NL6804983A (en) | 1968-10-21 |
| OA03386A (en) | 1970-12-15 |
| NO124997B (en) | 1972-07-03 |
| ES352822A1 (en) | 1969-11-16 |
| SE361884B (en) | 1973-11-19 |
| BE713802A (en) | 1968-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO140977B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-AMINO-1,4-DIHYDROPYRIDINES | |
| IL36239A (en) | 4-hydroxy-4-(2-oxo-3-tetrahydrofuryl)piperidine and its preparation | |
| NO125911B (en) | ||
| JPS6113472B2 (en) | ||
| SU843749A3 (en) | Method of preparing 4a,9b-trans-hexahydro-gamma-carboline | |
| IE43847B1 (en) | N-substituted phenyl-piperidine derivatives | |
| Toki | Studies on sarkomycin–optically active 2-methylenecyclopentanone-3-carboxylic acids | |
| US2678317A (en) | N - benzhydryltropylamine com | |
| US4087426A (en) | Oxybisberberine and a process for its production | |
| US3466298A (en) | Process for the preparation of 2-(2-aminoethyl)isoindolines | |
| Akkerman et al. | Synthetic oxytocics. IV. 3‐(piperidyl‐(2)‐methyl‐) indoles and related compounds | |
| US3072648A (en) | X-phenyl-s | |
| US3462443A (en) | Indeno(1,2-c)pyridine derivatives | |
| US3073826A (en) | 3-pyrrolidylmethyl-4-quinazolones | |
| US2956058A (en) | Novel substituted piperidines and pyrrolidines | |
| JP4994772B2 (en) | Method for producing piperidin-4-one derivative using bisaminol ether compound | |
| US2951080A (en) | Novel phenyl-substituted piperidines | |
| US2931805A (en) | Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines] | |
| IE41462B1 (en) | Piperidyl-methylenedioxybenzene derivatives | |
| US3086972A (en) | Aza-thiaxanthene derivatives | |
| GRUNDMANN et al. | Triazines. XVII. s-Triazine from s-Triazine-2, 4, 6-tricarbonic Acid | |
| NO139050B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTICALLY ACTIVE NORORIPAVIN AND TEBAIN DERIVATIVES | |
| US3037986A (en) | 2-(para-methoxyphenylcarbinol)-1-(phenylalkyl) piperidinium hydrobromide | |
| Belleau | SYNTHESIS IN THE FIELD OF THE ERYTHRINA ALKALOIDS: PART II. APPROACHES TO THE RING SYSTEM OF β-ERYTHROIDINE | |
| NO762085L (en) |